Early Prediction and Warning for Cardiotoxicity Due to Anthracycline-Based Breast Cancer Chemotherapy
Trial Parameters
Brief Summary
This multicenter clinical study aims to build an intelligent and accurate diagnosis and dynamic prediction and early warning model of cardiotoxicity due to anthracycline-based breast cancer chemotherapy, clarify the value of the early warning model in guiding the targeted prevention of myocardial protection, providing an important theoretical basis for reducing the mortality rate of breast cancer and improving the prognosis.
Eligibility Criteria
Inclusion Criteria: * Age ≥18 years * Histologically or cytopathological confirmed stage I-III HER2+ breast cancer, scheduled to receive consecutive anthracycline chemotherapy or subsequent sequential trastuzumab targeted therapy * LVEF≥53% before chemotherapy Exclusion Criteria: * life expectancy ≤12 months * Participating in other ongoing oncology clinical trials * Prior treatment with anthracyclines or chest radiation therapy * Pregnant or lactating women * Ultrasound images of the heart are of very poor quality